First-in-Human Study of 89Zr-DFO-HuMab-5B1 (MVT-2163) PET/CT imaging with and without HuMab-5B1 (MVT-5873) in patients with pancreatic cancer and other CA 19-9 positive malignancies

Conclusion: 89Zr-DFO-HuMab-5B1 PET/CT imaging with HuMab-5B1 is safe and demonstrates promising results for the detection of CA 19-9 positive malignancies. Further studies correlating imaging findings with histopathology are warranted to assess the accuracy of this imaging modality for detection of CA19-9 positive malignancies. Research Support: The clinical study was funded partly by the David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center. $$graphic_85017D82-A209-4243-A374-D23F153E67F1$$

Source: Journal of Nuclear Medicine - May 24, 2017 Category: Nuclear Medicine Authors: Lohrmann, C., O'Reilly, E., ODonoghue, J., Yu, K. H., Pandit-Taskar, N., Lyashchenko, S., Ruan, S., Wu, J., DeNoble, P., Carrasquillo, J., Schmidtlein, C., Teng, R., Lowery, M. A., Varghese, A., Estrella, H., Scholz, W., Maffuid, P., Lewis, J., Weber, W. Tags: New Clinical Concepts and First-in-Human Source Type: research